Microdosing isn't for everyone. While much of the conversation focuses on potential benefits, there are genuine reasons why some people should not microdose—or should approach it with extreme caution and professional guidance.
This isn't about gatekeeping. It's about honesty and safety. The same properties that make psychedelics potentially helpful—their ability to shift perception, alter mood, and change thought patterns—also mean they carry real risks for certain people.
Absolute Contraindications
Personal history of psychotic disorders. If you have been diagnosed with schizophrenia, schizoaffective disorder, or have experienced psychotic episodes, microdosing is strongly discouraged. Psychedelics activate serotonin 2A receptors in ways that can trigger or worsen psychotic symptoms. Even at very low doses, this risk exists.
Strong family history of psychosis. If you have a first-degree relative (parent or sibling) with schizophrenia or a related psychotic disorder, the risk increases significantly. Many psychotic disorders emerge in early adulthood, and psychedelic use—even microdosing—may accelerate or trigger onset in genetically vulnerable individuals.
Bipolar disorder, particularly type I. Psychedelics can potentially trigger manic episodes, especially in people with a history of severe mania. Some people with bipolar II have reported positive experiences with microdosing, but this remains an area of significant uncertainty and risk. If you have any bipolar diagnosis, proceed only with professional guidance.
Pregnancy and breastfeeding. There is essentially no data on the effects of microdosing during pregnancy or breastfeeding. We don't know how these substances affect fetal development or whether they pass into breast milk in meaningful amounts. Until that data exists, the cautious choice is clear.
Medication Conflicts
For a deeper look at how specific drugs interact with microdosing substances, see our full guide on medication interactions.
MAOIs (monoamine oxidase inhibitors). The combination of MAOIs with psychedelics—particularly tryptamines like psilocybin—can be dangerous. MAOIs prevent the breakdown of serotonin and other neurotransmitters, and adding a serotonin-active substance can lead to serotonin syndrome, which can be life-threatening. Common MAOIs include phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), and selegiline (Emsam). The antibiotic linezolid (Zyvox) also has MAOI properties.
Lithium. The combination of lithium and psychedelics has been associated with seizures and other severe adverse reactions. This is one of the clearest and most dangerous interactions. If you take lithium, do not microdose.
Conditions Requiring Caution
Heart conditions. Psychedelics interact with serotonin 2B receptors, which are involved in heart valve function. While the risk from microdosing is theoretical rather than demonstrated, anyone with existing heart valve problems or significant cardiovascular conditions should consult a cardiologist and exercise caution. Our heart health guide covers this topic in detail.
Severe anxiety disorders. While many people report that microdosing helps with anxiety, it can also temporarily increase it—especially in the early days of a protocol. People with severe anxiety or panic disorder may find that even small doses amplify their symptoms.
Active substance abuse. Psychedelics may eventually have a role in addiction treatment, but microdosing during active substance abuse—particularly with stimulants, other psychedelics, or substances that affect serotonin—adds complexity and risk. Stability first.
Dissociative disorders. People who experience dissociation, derealization, or depersonalization should be cautious. Psychedelics can blur the boundaries of self-perception in ways that may worsen these experiences.
Acute emotional crisis. If you're in the middle of a severe depressive episode, experiencing suicidal thoughts, processing recent trauma, or dealing with a major life upheaval, microdosing is not a first-line response. Stabilize first, ideally with professional support.
Situational Factors
Drug testing. Standard 5-panel and 10-panel drug tests don't typically screen for psilocybin or LSD. However, specialized tests exist, and some professional contexts use them. Psilocybin can be detected for 24–48 hours after use. If your employment, legal situation, or professional licensing could be affected, consider this carefully. Our overview of the legal landscape provides more context on legality by jurisdiction.
Legal situations. If you're on probation, involved in custody disputes, or in any legal situation where substance use could have consequences, the risk-benefit calculation shifts dramatically.
Lack of basic stability. Microdosing works best as part of a broader foundation of wellbeing. If you're struggling with housing, food security, or basic structure in your life, adding a psychoactive substance is unlikely to help and may add confusion.
Age considerations. Adolescent and young adult brains are still developing—the prefrontal cortex doesn't fully mature until the mid-twenties. At the other end, older adults often take multiple medications and may have cardiovascular concerns that warrant extra caution.
Being Honest with Yourself
Many of these situations are temporary. Not being a good candidate for microdosing now doesn't mean never. But the desire for microdosing to work shouldn't override honest assessment of whether it's appropriate for your specific situation.
If you're uncertain, talking to a healthcare provider—ideally one who understands psychedelics without dismissing them—is the safest path. And if a trusted voice suggests waiting, that's worth taking seriously.